EMA consults on guidance for RNA-based veterinary therapies

29th July 2026

Summary: The proposed guideline will provide detailed quality and safety requirements for RNA interference and RNA antisense oligonucleotide therapies, which are recognised as novel veterinary therapies under Regulation (EU) 2019/6. It is intended to support implementation of the Regulation by clarifying requirements not already addressed in existing general guidance for veterinary medicinal products. Stakeholders are invited to submit comments by 31st October 2026.

Link: https://www.ema.europa.eu/en/quality-safety-aspects-rna-interference-rna-antisense-oligonucleotide-therapies-veterinary-medicinal-products

Back to Recent News